My watch list
my.bionity.com  

my.bionity.com

With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

Proteolix, Inc.



This article needs additional citations for verification.
Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (August 2007)

Proteolix, Inc., is a private biotechnology company with its headquarters in South San Francisco, California. Proteolix focuses primarily on the proteasome as a therapeutic target. Its lead product candidate, carfilzomib (PR-171), is a tetrapeptide epoxyketone currently in both Phase 1 and Phase 2 clinical trials in the United States and Canada. Carfilzomib's current route of administration is intravenous, and the company is exploring its potential utility in multiple myeloma, Non-Hodgkin lymphoma (NHL) and other cancers.

Proteolix's corporate website is [1].

 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Proteolix,_Inc.". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE